Cyclopropylamine → (R)-6-(5-(cyclopropylamino)-1,3,4-oxadiazol-2-yl)-4-((3,3-dimethylpiperidin-4-yl)amino)pyrrolo[1,2-b]pyridazine-3-carboxamide
Reaktionsgleichung
[CH:1]1([NH2:4])[CH2:3][CH2:2]1.[C:5]([C:8]1[CH:13]=[N:12][N:11]2[CH:14]=[C:15]([C:17]3[O:18][C:19](S(C)=O)=[N:20][N:21]=3)[CH:16]=[C:10]2[C:9]=1[NH:25][C@@H:26]1[CH2:31][CH2:30][N:29](C(OC(C)(C)C)=O)[CH2:28][C:27]1([CH3:40])[CH3:39])(=[O:7])[NH2:6]>>[CH:1]1([NH:4][C:19]2[O:18][C:17]([C:15]3[CH:16]=[C:10]4[C:9]([NH:25][C@@H:26]5[CH2:31][CH2:30][NH:29][CH2:28][C:27]5([CH3:40])[CH3:39])=[C:8]([C:5]([NH2:6])=[O:7])[CH:13]=[N:12][N:11]4[CH:14]=3)=[N:21][N:20]=2)[CH2:3][CH2:2]1Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
Cyclopropanamine (0.067 mL, 0.966 mmol) was added to a crude solution of (4R)-tert-butyl 4-((3-carbamoyl-6-(5-(methylsulfinyl)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)amino)-3,3-dimethylpiperidine-1-carboxylate (⅙ of the total volume from Step 5, 0.097 mmol maximum). After 22 h at room temperature, the reaction was complete. The mixture was concentrated in vacuo. The crude material was dissolved in dichloromethane (0.5 mL) and treated with trifluoroacetic acid (0.100 mL). After stirring overnight at room temperature, the Boc-deprotection was approximately 50% complete. Additional trifluoroacetic acid (0.185 mL) was added. After 30 min at room temperature, the deprotection was complete. The mixture was concentrated and triturated with ether. The ether layer was decanted. The solid residue was used in the next reaction without purification.